Literature DB >> 15555643

Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig.

Weifang Rong1, Geoffrey Burnstock.   

Abstract

This study was conducted to determine whether adenosine 5'-triphosphate (ATP) contributes to nociceptor activity induced by ureter distension. Multifibre recordings of ureter afferents were made using the guinea pig ureter preparation perfused in vitro. Distension of the ureter resulted in an initial rapid and later maintained increase in afferent nerve discharge. Intraluminal application of ATP (10-1000 microM, 0.1 ml/min for 3 min) or alpha,beta-meATP (10-1000 microM) mimicked these increases in afferent activity. The afferent responses consisted of fast and slow components. Both agonists caused a sensitisation of the afferents to ureter distensions. TNP-ATP (30 microm), a P2X3 receptor antagonist, and the non-specific P2 antagonist, PPADS (100 microm), blocked the rapid and reduced the slower response to ATP. The remaining responses were blocked by the selective A1 receptor antagonist, DPCPX. TNP-ATP and PPADS reduced distension-induced afferent activity. The selective ecto-ATPase inhibitor, ARL-67156 (100, 200 microM) and suramin (100, 200 microM), an ecto-nucleotidase inhibitor as well as a P2 receptor antagonist, produced an increase in baseline and distension-induced discharge. These results indicate that the ureter epithelium may tonically (at rest) as well as phasically (on distension) release ATP, which stimulates afferent terminals by interacting with multiple P2 and P1 receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555643     DOI: 10.1016/j.neuropharm.2004.08.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  14 in total

Review 1.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

Review 2.  Cell biology and physiology of the uroepithelium.

Authors:  Puneet Khandelwal; Soman N Abraham; Gerard Apodaca
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-08

Review 3.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

4.  Purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Altered expression of P2X3 in vagal and spinal afferents following esophagitis in rats.

Authors:  Banani Banerjee; Bidyut K Medda; Jamie Schmidt; Yue Zheng; Zhihong Zhang; Reza Shaker; Jyoti N Sengupta
Journal:  Histochem Cell Biol       Date:  2009-09-26       Impact factor: 4.304

Review 6.  Visceral pain: the neurophysiological mechanism.

Authors:  Jyoti N Sengupta
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  Purinergic signalling in the urinary tract in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

8.  In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization.

Authors:  Anthony P Ford
Journal:  Purinergic Signal       Date:  2011-11-18       Impact factor: 3.765

Review 9.  Purinergic mechanosensory transduction and visceral pain.

Authors:  Geoffrey Burnstock
Journal:  Mol Pain       Date:  2009-11-30       Impact factor: 3.395

10.  ATP release from the human ureter on distension and P2X(3) receptor expression on suburothelial sensory nerves.

Authors:  R C Calvert; C S Thompson; G Burnstock
Journal:  Purinergic Signal       Date:  2008-09-26       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.